ArticleThe Journal of infectious diseases2019
Protective Efficacy of Nucleic Acid Vaccines Against Transmission of Zika Virus During Pregnancy in Mice.
Article in The Journal of infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 52 citations in OpenAlex.
- A Zika virus vaccine with E protein fusion loop mutations protects via CD8Nature microbiology · 2026Article
- Review
- Review
- MHCI trafficking signal-based mRNA vaccines strengthening immune protection against RNA viruses.Bioengineering & translational medicine · 2025Article
- Non-Viral RNA Delivery During Pregnancy: Opportunities and Challenges.Small (Weinheim an der Bergstrasse, Germany) · 2024Review
- Efficient signal sequence of mRNA vaccines enhances the antigen expression to expand the immune protection against viral infection.Journal of nanobiotechnology · 2024Article
- Messenger RNA Therapy for Female Reproductive Health.Molecular pharmaceutics · 2024Review
- Development of nucleic acid-based vaccines against dengue and other mosquito-borne flaviviruses: the past, present, and future.Frontiers in immunology · 2024Review
- Induction of long-term tolerance to a specific antigen using anti-CD3 lipid nanoparticles following gene therapy.Molecular therapy. Nucleic acids · 2023Article
- Mechanism of Immune Evasion in Mosquito-Borne Diseases.Pathogens (Basel, Switzerland) · 2023Review
- Review
- A Comprehensive Review of mRNA Vaccines.International journal of molecular sciences · 2023Review
- Control of maternal Zika virus infection during pregnancy is associated with lower antibody titers in a macaque model.Frontiers in immunology · 2023Article
- Diagnostic and vaccine potential of Zika virus envelope protein (E) derivates produced in bacterial and insect cells.Frontiers in immunology · 2023Article
- mRNA vaccines for COVID-19 and diverse diseases.Journal of controlled release : official journal of the Controlled Release Society · 2022Review
- Measles-based Zika vaccine induces long-term immunity and requires NS1 antibodies to protect the female reproductive tract.NPJ vaccines · 2022Article
- Advances in COVID-19 mRNA vaccine development.Signal transduction and targeted therapy · 2022Review
- Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases.RNA biology · 2022Review
- Messenger RNA-Based Vaccines Against Infectious Diseases.Current topics in microbiology and immunology · 2022Review
- mRNA vaccines for infectious diseases: principles, delivery and clinical translation.Nature reviews. Drug discovery · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
Abstract
Zika virus (ZIKV) caused an epidemic of congenital malformations in 2015-2016. Although many vaccine candidates have been generated, few have demonstrated efficacy against congenital ZIKV infection. Here, we evaluated lipid-encapsulated messenger RNA (mRNA) vaccines and a DNA plasmid vaccine encoding the prM-E genes of ZIKV in mouse models of congenital infection. Although the DNA vaccine provided comparable efficacy against vertical transmission of ZIKV, the mRNA vaccines, including one that minimizes antibody-dependent enhancement of infection, elicited higher levels of antigen-specific long-lived plasma cells and memory B cells. Despite the induction of robust neutralizing antibody titers by all vaccines, breakthrough seeding of the placenta and fetal head was observed in a small subset of type I interferon signaling-deficient immunocompromised dams. In comparison, evaluation of one of the mRNA vaccines in a human STAT2-knockin transgenic immunocompetent mouse showed complete protection against congenital ZIKV transmission. These data will inform ongoing human ZIKV vaccine development efforts and enhance our understanding of the correlates of vaccine-induced protection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.